脱敏疗法联合布地奈德/福莫特罗粉吸入剂治疗过敏性支气管哮喘疗效观察

Desensitization therapy combined with budesonide/symbicort inhalant for treatment of allergic bronchial asthma

目的 观察脱敏疗法与布地奈德/福莫特罗粉吸入剂联合用于过敏性支气管哮喘患者的疗效.方法 80例过敏性支气管哮喘患者患者按随机数字表法分为观察组和对照组,每组40例.两组患者均给予常规处理和脱敏疗法,对照组按需给予糖皮质激素,观察组给予布地奈德/福莫特罗粉吸入剂.比较两组肺功能、症状评分和不良反应,并评价疗效.结果 观察组总有效率为92.5％ （37/40）,明显高于对照组的72.5％（29/40）（x2=4.76,P＜0.05）.两组治疗后1秒钟呼吸容积占预计值的百分比、呼气峰流速值及症状评分均较治疗前明显改善（t=7.92、6.98、5.56、4.42、4.10、4.03,均P＜0.05）,观察组改善较对照组更为显著（t=4.83、4.23、4.60,均P＜0.05）.观察组不良反应发生率为15.0％ （6/40）,明显少于对照组的35.0％ （14/40）（x2=4.20,P＜0.05）.结论 脱敏疗法与布地奈德/福莫特罗粉吸入剂联合具有很好的改善哮喘症状和肺功能作用,可使更多患者达到并维持哮喘临床控制,安全性高,值得临床推广应用.

Objective To investigate the desensitization therapy combined with budesonide/symbicort inhal- ant for treatment of allergic bronchial asthma. Methods 80 patients with allergic asthma randomly divided into obser- vation group and control group, each group of 40 eases. Two groups were given conventional treatment and desensitiza- tion therapy, the control group required glucocorticoid, the observation group received budesonide/symbicort inhalant. were evaluated. Results The total effective rate in the observation group was 92.5 % （37/40）, the control group was 72.5% （29/40）, the difference was statistically significant（ P 〈 0.05 ）. FEV1.0 % in the two groups after treatment, PET and symptom score were significantly improved after treatment（ P 〈 0.05 ）. The observation group improved moresignificantly than that of the control group （P 〈 0.05 ）. The incidence of adverse reaction in observation group was 15% （6/40）, significantly less than that in the control group 55% （14/40）, the difference was statistically significant （P 〈 0.05）. Conclusion Desensitization therapy combined with budesonide/symbicort inhalant in asthma symptoms could improve asthma and lung function, which has high safety and worthy of clinical application.